Patient Preferences and Patient Experience projects focus uniquely on the evolving needs of survivors and their caregivers, including how their treatment preferences have changed with the progress in science, and how they are living with and experiencing the disease.

The treatment landscape of lung cancer is rapidly evolving, with the development of genetically targeted therapies and immunotherapy. Since 2015, the US Food and Drug Administration (FDA) has approved 44 new treatment approaches for lung cancer.

With this evolution in the science come questions whose answers are important:

  1. How have the needs of patients and their caregivers evolved with the change in science? How do these needs intersect with factors associated with lung cancer diagnosis (such as histology and stage of diagnosis)?
  2. The side effects and toxicities associated with new treatments can be significant. With the emergence of new treatment options for lung cancer, the complexity of treatment decisions for people living with lung cancer has increased. What do patients really want from their treatment? Better quality of life? Extended survival? Other benefits?
  3. How is lung cancer care delivered in the real-world outside clinical trial settings? How are lung cancer treatments sequenced and how does treatment sequencing impact patient outcomes and quality of life?